Abstract
Sixteen patients with advanced metastatic malignant melanoma were treated with a high-dose infusion of interleukin-2 (IL-2; 18×106 IU/m−2 day−1) together with daily subcutaneous (s.c.) injections of interferon α (IFNα; 3×106 U/m−2 day−1) in 5-day cycles. Nine of these patients were given histamine (1 mg s.c.) twice daily during treatment with IL-2 and IFNα. In the seven patients who did not receive histamine, one partial response (that is a reduction of more than 50% in the total tumour burden) was observed in a patient with skin and lymph node melanoma. In the eight histamine-treated patients evaluable for response, four partial responses were observed. Two other patients showed regression at one site of metastasis but tumours remained unchanged at other sites. Two histamine-treated patients showed complete resolution of extensive liver metastasis. Sites of response in histamine-treated patients also included the subcutis, lymph nodes, skeleton, spleen and muscle. Lung melanoma did not respond to histamine/IL-2/IFNα. Three patients with lung tumours responded with significant (more than 50%) reduction of the volume of soft-tissue tumours, suggesting that the response to histamine may be organotropic. Survival was significantly prolonged in patients receiving histamine. Our data suggest that treatment with histamine may improve the antitumour efficacy of immunotherapy in metastatic melanoma.
Key words: Histamine, NK cells, Melanoma, Interleukin-2, Interferon α, Immunotherapy
References
- 1.Bar MH, Sznol M, Atkins MB, et al. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J Clin Oncol. 1990;8:1138–1147. doi: 10.1200/JCO.1990.8.7.1138. [DOI] [PubMed] [Google Scholar]
- 2.Bergmann L, Weidmann E, Mitrou PS, et al. Interleukin-2 in combination with interferon-α in disseminated malignant melanoma and advanced renal cell carcinoma. Onkologie. 1990;13:137–140. doi: 10.1159/000216741. [DOI] [PubMed] [Google Scholar]
- 3.Brunda MJ, Belantoni D, Sulich V. In vivo antitumour activity of combinations of interferon-α and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic function resembling natural killer cells. Int J Cancer. 1987;40:365–371. doi: 10.1002/ijc.2910400314. [DOI] [PubMed] [Google Scholar]
- 4.Hellstrand K, Hermodsson S. Histamine H2-receptor mediated regulation of human natural killer cell cytotoxicity. J Immunol. 1986;137:656–660. [PubMed] [Google Scholar]
- 5.Hellstrand K, Hermodsson S. A cell-to-cell interaction involving monocytes and non-T/CD16+ natural killer (NK) cells is required for histamine H2-receptor mediated NK cell activation. Scand J Immunol. 1990;31:631–645. doi: 10.1111/j.1365-3083.1990.tb02814.x. [DOI] [PubMed] [Google Scholar]
- 6.Hellstrand K, Hermodsson S. Synergistic NK cell activation by histamine and interleukin-2. Int Arch Allergy Appl Immunol. 1990;92:379–389. doi: 10.1159/000235169. [DOI] [PubMed] [Google Scholar]
- 7.Hellstrand K, Hermodsson S. Cell-to-cell mediated inhibition of natural killer cell proliferation by monocytes and its regulation by histamine H2-receptors. Scand J Immunol. 1991;34:741–752. doi: 10.1111/j.1365-3083.1991.tb01599.x. [DOI] [PubMed] [Google Scholar]
- 8.Hellstrand K, Asea A, Hermodsson S. Role of histamine in natural killer cell mediated resistance against tumor cells. J Immunol. 1990;145:4365–4370. [PubMed] [Google Scholar]
- 9.Hellstrand K, Kylefjord H, Asea A, Hermodsson S. Regulation of the NK-cell response to IFN-α by biogenic amines. J Interferon Res. 1992;12:199–206. doi: 10.1089/jir.1992.12.199. [DOI] [PubMed] [Google Scholar]
- 10.Hersh E, Lee Murray J, Ki Hong W, et al. Phase I study of cancer therapy with recombinant interleukin-2 administered by intravenous bolus injection. Biotherapy. 1989;1:215–226. doi: 10.1007/BF02170890. [DOI] [PubMed] [Google Scholar]
- 11.Oldham RK, Blumenschein G, Schwartzberg L, et al. Combination biotherapy utilizing interleukin-2 and α interferon in patients with advanced cancer: a National Biotherapy Study Group Trial. Mol Biother. 1992;4:4–9. [PubMed] [Google Scholar]
- 12.Parkinson DR, Abrams JS, Wiernik PH, et al. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol. 1990;8:1650–1656. doi: 10.1200/JCO.1990.8.10.1650. [DOI] [PubMed] [Google Scholar]
- 13.Thatcher N. Recombinant interleukin-2 and other types of treatment of advanced malignant melanoma. Curr Opin Oncol. 1991;3:364–376. doi: 10.1097/00001622-199104000-00020. [DOI] [PubMed] [Google Scholar]
- 14.Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187–376. doi: 10.1016/S0065-2776(08)60664-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Whitehead RP, Kopecky K, Samson MK, et al. Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study. J Natl Cancer Inst. 1991;83:1250–1253. doi: 10.1093/jnci/83.17.1250. [DOI] [PubMed] [Google Scholar]
- 16.Whitehead RP, Figlin R, Citron ML, et al. A phase II trial of concomitant human interleukin-2 and interferon α-2a in patients with disseminated malignant melanoma. J Immunother. 1992;13:177–221. doi: 10.1097/00002371-199302000-00006. [DOI] [PubMed] [Google Scholar]